Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Syndax Pharmaceuticals, Inc. (SNDX : NSDQ)
 
 • Company Description   
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.

Number of Employees: 270

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.00 Daily Weekly Monthly
20 Day Moving Average: 1,639,238 shares
Shares Outstanding: 86.05 (millions)
Market Capitalization: $774.43 (millions)
Beta: 0.70
52 Week High: $25.07
52 Week Low: $8.58
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -21.40% -24.89%
12 Week -19.35% -31.12%
Year To Date -31.92% -36.23%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
730 Third Avenue 9th Floor
-
New York,NY 10017
USA
ph: 781-419-1400
fax: 781-419-1420
ir@syndax.com http://www.syndax.com
 
 • General Corporate Information   
Officers
Michael A. Metzger - Chief Executive Officer and Director
Dennis G. Podlesak - Chairman
Keith A. Goldan - Chief Financial Officer
Martin H. Huber - Director
Jennifer Jarrett - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87164F105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 86.05
Most Recent Split Date: (:1)
Beta: 0.70
Market Capitalization: $774.43 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.81 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.61 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 25.79% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.60
Price/Cash Flow: -
Price / Sales: 17.71
EPS Growth
vs. Year Ago Period: -15.29%
vs. Previous Quarter: 10.91%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 160.96%
ROE
06/30/25 - -
03/31/25 - -101.60
12/31/24 - -80.66
ROA
06/30/25 - -
03/31/25 - -58.41
12/31/24 - -58.74
Current Ratio
06/30/25 - -
03/31/25 - 5.80
12/31/24 - 5.82
Quick Ratio
06/30/25 - -
03/31/25 - 5.75
12/31/24 - 5.82
Operating Margin
06/30/25 - -
03/31/25 - -757.53
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -757.53
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -757.52
12/31/24 - -1,346.11
Book Value
06/30/25 - -
03/31/25 - 2.50
12/31/24 - 3.38
Inventory Turnover
06/30/25 - -
03/31/25 - 1.36
12/31/24 - 9.03
Debt-to-Equity
06/30/25 - -
03/31/25 - 1.53
12/31/24 - 1.15
Debt-to-Capital
06/30/25 - -
03/31/25 - 60.52
12/31/24 - 53.51
 

Powered by Zacks Investment Research ©